Olema Pharmaceuticals (OLMA) Short Interest Ratio & Short Volume $5.16 +0.15 (+2.99%) Closing price 04:00 PM EasternExtended Trading$5.17 +0.01 (+0.19%) As of 06:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Short Interest Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock Olema Pharmaceuticals Short Interest DataOlema Pharmaceuticals (OLMA) has a short interest of 5.43 million shares. This marks a -10.69% decrease in short interest from the previous month. The short interest ratio (days to cover) is 5.7, indicating that it would take 5.7 days of the average trading volume of 860,866 shares to cover all short positions.Current Short Interest5,430,000 sharesPrevious Short Interest6,080,000 sharesChange Vs. Previous Month-10.69%Dollar Volume Sold Short$28.02 millionShort Interest Ratio5.7 Days to CoverLast Record DateApril 30, 2025Outstanding Shares68,421,000 sharesPercentage of Shares Shorted7.94%Today's Trading Volume387,845 sharesAverage Trading Volume860,866 sharesToday's Volume Vs. Average45% Short Selling Olema Pharmaceuticals? Sign up to receive the latest short interest report for Olema Pharmaceuticals and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort Interest ChartDays to Cover ChartShort Percent of Float ChartOLMA Short Interest Over TimeOLMA Days to Cover Over TimeOLMA Percentage of Float Shorted Over Time Olema Pharmaceuticals Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 4/30/20255,430,000 shares $28.02 million -10.7%N/A5.7 $5.16 4/15/20256,080,000 shares $25.60 million -6.5%13.2%6.1 $4.21 3/31/20256,500,000 shares $24.44 million -25.2%14.1%6 $3.76 3/15/20258,690,000 shares $38.32 million +2.6%18.8%8 $4.41 2/28/20258,470,000 shares $37.01 million +3.0%18.3%7.5 $4.37 2/15/20258,220,000 shares $40.85 million -2.3%17.8%7.5 $4.97 1/31/20258,410,000 shares $51.39 million -22.6%N/A7.9 $6.11 1/15/202510,870,000 shares $60.00 million +4.5%N/A11.5 $5.52 12/31/202410,400,000 shares $60.63 million +4.3%N/A12.8 $5.83 12/15/20249,970,000 shares $67.30 million -0.5%N/A14.9 $6.75 Get the Latest News and Ratings for OLMA and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Olema Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. 11/30/202410,020,000 shares $101.40 million +17.1%N/A19.5 $10.12 11/15/20248,560,000 shares $78.50 million +3.0%N/A17.6 $9.17 10/31/20248,310,000 shares $95.81 million -2.2%N/A17.9 $11.53 10/15/20248,500,000 shares $99.03 million -0.1%N/A15.8 $11.65 9/30/20248,510,000 shares $101.61 million -3.6%N/A14.2 $11.94 9/15/20248,830,000 shares $112.14 million -0.1%N/A13.4 $12.70 8/31/20248,840,000 shares $104.31 million +3.0%N/A12.7 $11.80 8/15/20248,580,000 shares $106.31 million +6.7%N/A9.2 $12.39 7/31/20248,040,000 shares $129.93 million +10.0%N/A8.3 $16.16 7/15/20247,310,000 shares $96.05 million +14.6%N/A7.7 $13.14 6/30/20246,380,000 shares $69.03 million -18.0%N/A6.8 $10.82 6/15/20247,780,000 shares $96.16 million -4.8%N/A8.4 $12.36 5/31/20248,170,000 shares $79.09 million -4.3%N/A7.9 $9.68 5/15/20248,540,000 shares $84.12 million +1.7%N/A10.4 $9.85 4/30/20248,400,000 shares $85.43 million -6.4%N/A10.5 $10.17 4/15/20248,970,000 shares $97.32 million +10.7%N/A11.1 $10.85 3/31/20248,100,000 shares $91.69 million +60.1%N/A9.9 $11.32 3/15/20245,060,000 shares $58.44 million +3.9%N/A6.4 $11.55 2/29/20244,870,000 shares $60.39 million -21.2%N/A5.9 $12.40 2/15/20246,180,000 shares $91.53 million -7.9%N/A6.8 $14.81 1/31/20246,710,000 shares $87.50 million -5.2%N/A7.5 $13.04 1/15/20247,080,000 shares $82.13 million +0.7%N/A8.3 $11.60 12/31/20237,030,000 shares $98.63 million +5.7%N/A8.5 $14.03 12/15/20236,650,000 shares $81.13 million +27.6%N/A8.5 $12.20 11/30/20235,210,000 shares $72.68 million +88.8%N/A8.1 $13.95 11/15/20232,760,000 shares $46.42 million No ChangeN/A6.4 $16.82 10/31/20232,760,000 shares $36.68 million +26.0%7.3%7.9 $13.29 10/15/20232,190,000 shares $27.66 million +10.6%5.8%7.6 $12.63 9/30/20231,980,000 shares $24.45 million +12.5%5.4%7.1 $12.35 9/15/20231,760,000 shares $22.69 million +10.7%4.8%5.9 $12.89Vladimir Lenin was right… (Ad)The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold $3 billion of Amazon… it’s why Nvidia’s CEO just sold $713 million... and it’s why Zuckerberg just sold $1.3 billion in Meta stock. The financial establishment doesn’t want you to know about this… but a controversial new documentary just pulled back the curtain and exposed what’s really going on. It’s called The Final Frontier.Including the name of the #1 company to buy. 8/31/20231,590,000 shares $16.14 million -9.7%4.4%4.1 $10.15 8/15/20231,760,000 shares $19.03 million -4.4%5.0%4.8 $10.81 7/31/20231,840,000 shares $15.92 million -4.7%5.3%5.1 $8.65 7/15/20231,930,000 shares $15.81 million +5.5%5.6%5.4 $8.19 6/30/20231,830,000 shares $16.52 million +55.1%5.3%5 $9.03 6/15/20231,180,000 shares $10.71 million +14.6%3.4%3.7 $9.08 5/31/20231,030,000 shares $5.33 million No Change3.0%5.2 $5.17 5/15/20231,030,000 shares $6.89 million +1.0%3.0%6.2 $6.69 4/30/20231,020,000 shares $4.89 million -6.4%3.0%6 $4.79 4/15/20231,090,000 shares $3.99 million -4.4%3.2%6.5 $3.66 3/31/20231,140,000 shares $3.96 million +3.6%3.3%6.3 $3.47 3/15/20231,100,000 shares $4.38 million -1.8%3.2%7.5 $3.98 2/28/20231,120,000 shares $4.59 million -21.1%3.3%7.5 $4.10 2/15/20231,420,000 shares $6.38 million No Change4.1%9.1 $4.49 1/31/20231,420,000 shares $6.86 million -7.2%4.1%8.7 $4.83 1/15/20231,530,000 shares $6.35 million +1.3%4.5%10.3 $4.15 12/30/20221,510,000 shares $3.70 million -5.6%4.4%12.5 $2.45 12/15/20221,600,000 shares $3.92 million +1.3%4.7%12.3 $2.45 11/30/20221,580,000 shares $4.53 million -3.1%4.6%10.7 $2.87 11/15/20221,630,000 shares $5.22 million +4.5%4.7%10.2 $3.20 10/31/20221,560,000 shares $5.87 million +3.3%4.5%8 $3.76 10/15/20221,510,000 shares $4.32 million -3.2%4.4%7.3 $2.86 9/30/20221,560,000 shares $4.31 million -7.1%4.5%4.7 $2.76 9/15/20221,680,000 shares $6.89 million -6.2%4.9%4.2 $4.10 8/31/20221,790,000 shares $7.07 million -6.3%5.2%4 $3.95 8/15/20221,910,000 shares $8.16 million +6.1%5.6%3.7 $4.27 7/31/20221,800,000 shares $9.04 million +0.6%5.2%3.4 $5.02 7/15/20221,790,000 shares $8.41 million -14.8%5.2%3.3 $4.70 6/30/20222,100,000 shares $8.55 million -23.6%6.1%4.6 $4.07 6/15/20222,750,000 shares $10.20 million +10.9%8.1%6 $3.71 5/31/20222,480,000 shares $7.09 million -9.5%7.3%5.9 $2.86 5/15/20222,740,000 shares $5.92 million +1.5%8.1%6.9 $2.16 4/30/20222,700,000 shares $6.89 million +13.5%8.1%7.2 $2.55 4/15/20222,380,000 shares $7.33 million -18.2%7.2%5.7 $3.08 3/31/20222,910,000 shares $12.40 million +1.8%8.8%6.9 $4.26 3/15/20222,860,000 shares $11.13 million -5.0%8.6%6.3 $3.89 2/28/20223,010,000 shares $14.09 million +14.5%9.1%5.9 $4.68 2/15/20222,630,000 shares $13.47 million +0.8%7.9%3.1 $5.12 1/31/20222,610,000 shares $16.78 million +8.8%8.2%3.1 $6.43 1/15/20222,400,000 shares $16.06 million -37.5%7.6%3 $6.69 12/31/20213,840,000 shares $35.94 million +15.0%12.1%4.7 $9.36 12/15/20213,340,000 shares $30.69 million -17.9%10.5%4.2 $9.19 11/30/20214,070,000 shares $35.61 million +23.0%12.9%5.4 $8.75 11/15/20213,310,000 shares $87.02 million +22.6%10.5%8.6 $26.29 10/29/20212,700,000 shares $72.90 million +16.4%8.7%8 $27.00 10/15/20212,320,000 shares $71.25 million -3.7%7.5%7 $30.71 9/30/20212,410,000 shares $66.42 million +8.1%7.8%8.1 $27.56 9/15/20212,230,000 shares $60.81 million +8.3%7.2%7.8 $27.27 8/31/20212,060,000 shares $61.64 million +4.0%6.6%7.6 $29.92 8/13/20211,980,000 shares $53.06 million -17.8%6.4%7.8 $26.80Trump Predicts Dollar Downfall (Ad)READ THIS VERY CAREFULLY: If you have $100,000 or more saved for retirement, this may make you VERY angry... This is what President Trump said: "Our currency is crashing and will soon no longer be the world standard, which will be our greatest defeat, frankly, in 200 years." Why Would He Say This?Claim your free, no-strings-attached 2025 Ultimate Guide to Gold IRAs right now. 7/30/20212,410,000 shares $56.59 million -0.8%7.3%9.7 $23.48 7/15/20212,430,000 shares $60.51 million +7.5%7.2%10.5 $24.90 6/30/20212,260,000 shares $63.23 million +23.5%6.7%10.6 $27.98 6/15/20211,830,000 shares $55.83 million -5.2%5.4%8.6 $30.51 5/28/20211,930,000 shares $53.96 million +35.9%5.7%9.4 $27.96 5/14/20211,420,000 shares $34.18 million +6.8%4.2%7.5 $24.07 4/30/20211,330,000 shares $39.83 million +16.7%4.5%7.6 $29.95 4/15/20211,140,000 shares $40.88 million +32.4%3.5%7.1 $35.86 3/31/2021861,000 shares $24.90 million +94.8%2.6%5.5 $28.92 3/15/2021441,900 shares $20.82 million -4.6%1.4%3 $47.12 2/26/2021463,300 shares $19.29 million +4.0%1.5%4.6 $41.63 2/12/2021445,400 shares $23.50 million -4.7%1.4%2.9 $52.76 1/29/2021467,400 shares $19.67 million +14.9%1.4%2.9 $42.09 1/15/2021406,800 shares $16.83 million No Change1.2%2.3 $41.37 OLMA Short Interest - Frequently Asked Questions What is Olema Pharmaceuticals' current short interest? Short interest is the volume of Olema Pharmaceuticals shares that have been sold short but have not yet been closed out or covered. As of April 30th, traders have sold 5,430,000 shares of OLMA short. Learn More on Olema Pharmaceuticals' current short interest. What is a good short interest ratio for Olema Pharmaceuticals? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. OLMA shares currently have a short interest ratio of 6.0. Learn More on Olema Pharmaceuticals's short interest ratio. Is Olema Pharmaceuticals' short interest increasing or decreasing? Olema Pharmaceuticals saw a decrease in short interest in April. As of April 30th, there was short interest totaling 5,430,000 shares, a decrease of 10.7% from the previous total of 6,080,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. How does Olema Pharmaceuticals' short interest compare to its competitors? Here is how the short interest of companies in the industry of "pharmaceutical products" compare to Olema Pharmaceuticals: 89bio, Inc. (11.86%), Ocular Therapeutix, Inc. (8.15%), Amphastar Pharmaceuticals, Inc. (9.22%), Aurinia Pharmaceuticals Inc. (9.26%), Wave Life Sciences Ltd. (8.59%), Gyre Therapeutics, Inc. (13.99%), Phibro Animal Health Co. (4.52%), Mineralys Therapeutics, Inc. (16.91%), Collegium Pharmaceutical, Inc. (14.75%), Syndax Pharmaceuticals, Inc. (25.17%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: Spotify Technology S.A. ($4.67 billion), Charter Communications, Inc. ($4.58 billion), Capital One Financial Co. ($4.47 billion), The Kroger Co. ($2.56 billion), Reddit, Inc. ($2.23 billion), Rivian Automotive, Inc. ($2.16 billion), Live Nation Entertainment, Inc. ($1.90 billion), SoFi Technologies, Inc. ($1.85 billion), Zscaler, Inc. ($1.75 billion), and Omnicom Group Inc. ($1.75 billion). View all of the most shorted stocks. What does it mean to sell short Olema Pharmaceuticals stock? Short selling OLMA is an investing strategy that aims to generate trading profit from Olema Pharmaceuticals as its price is falling. OLMA shares are trading up $0.15 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Olema Pharmaceuticals? A short squeeze for Olema Pharmaceuticals occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of OLMA, which in turn drives the price of the stock up even further. How often is Olema Pharmaceuticals' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including OLMA, twice per month. The most recent reporting period available is April, 30 2025. More Short Interest Resources from MarketBeat Related Companies ETNB Short Squeeze OCUL Short Squeeze AMPH Short Squeeze AUPH Short Squeeze WVE Short Squeeze GYRE Short Squeeze PAHC Short Squeeze MLYS Short Squeeze COLL Short Squeeze SNDX Short Squeeze Short Interest Tools Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:OLMA) was last updated on 5/22/2025 by MarketBeat.com Staff From Our PartnersEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredMan who predicted $100K Bitcoin sees a huge run coming for another coin …Sure enough, Bitcoin took off on the exact day Juan said it would. It's up more than 40% since the election...Weiss Ratings | SponsoredTrump Predicts Dollar DownfallREAD THIS VERY CAREFULLY: If you have $100,000 or more saved for retirement, this may make you VERY angry... ...Augusta Precious Metals | SponsoredThe Secret Map of America, Declassified…Locked inside a Maryland man’s private safe is a map. But not just any map, mind you… This map shows a “...Banyan Hill Publishing | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredElon’s backup plan for AIElon knows the future isn’t about smarter AI — it’s about powering it. And this new technology is quietly b...True Market Insiders | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Olema Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Olema Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
